The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Long-term progression-free survival (PFS) and overall survival (OS) to pemetrexed (P) as single agent in metastatic urothelial carcinoma (MUC): A Spanish Oncology Genitourinary Group (SOGUG) systematic review.
J. M. Cervera Grau
No relevant relationships to disclose
Enrique Gonzalez-Billalabeitia
No relevant relationships to disclose
Francisco Ayala
No relevant relationships to disclose
Inmaculada Ballester Navarro
No relevant relationships to disclose
Antonio Lopez
No relevant relationships to disclose
Javier Garde
No relevant relationships to disclose
Oscar Juan Vidal
No relevant relationships to disclose
Jose Manuel Satre
No relevant relationships to disclose
Enrique Barrajon
No relevant relationships to disclose
Gaspar Esquerdo
No relevant relationships to disclose
Carmen Molins
No relevant relationships to disclose
Sonia MaciĆ”
No relevant relationships to disclose
Christian Diego Rolfo
No relevant relationships to disclose
Macarena Paz Espinoza Venegas
No relevant relationships to disclose